摘要
心肌灌注显像是诊断冠心病、评估冠状动脉病变程度和范围、评估疗效和判断预后的重要影像学方法。18 F标记的新型正电子心肌灌注显像剂包括亲脂性阳离子类显像剂和线粒体复合物Ⅰ(MC-Ⅰ)抑制剂类显像剂,其中MC-Ⅰ抑制剂Flurpiridaz已进入Ⅲ期临床试验。本文围绕18F标记的新型正电子心肌灌注显像剂摄取机制及特点及其应用前景进行综述。
Myocardial perfusion imaging is an important radiologic method to diagnose coronary heart disease, assess the extent of coronary stenosis, evaluate curative effect and predict prognosis. The novel myocardial perfusion imaging agents labeled with ^18F include lipophilic cations and analogues of mitochondrial complex Ⅰ （MC-Ⅰ） inhibitors, among them Flurpiridaz has been in phase Ⅲ clinical study. The absorption mechanism and characteristics of novel myocardial perfusion imaging agents labeled with ^18F and their application were reviewed in this article.
出处
《中国医学影像技术》
CSCD
北大核心
2014年第6期926-929,共4页
Chinese Journal of Medical Imaging Technology
